Nitroglycerin for Esophageal Spasm
Nitroglycerin can provide symptomatic relief for diffuse esophageal spasm, particularly in patients without concurrent gastroesophageal reflux, though the evidence supporting its use is limited to small observational studies from the 1970s-1990s rather than modern randomized controlled trials.
Mechanism and Rationale
Nitroglycerin acts as a smooth muscle relaxant through nitric oxide (NO)-mediated pathways, which may address the underlying pathophysiology of esophageal spasm 1. The drug reduces esophageal contractile amplitude and can elongate the latency period after swallowing, potentially alleviating the premature, rapidly propagated contractions characteristic of distal esophageal spasm 1, 2.
Clinical Evidence
Efficacy in Diffuse Esophageal Spasm
Patients without reflux: In a 1977 study of 5 patients with diffuse esophageal spasm (DES) without gastroesophageal reflux, nitroglycerin produced uniformly good responses both manometrically and clinically 3. These patients remained symptom-free on long-acting nitrates for 6 months to 4 years 3.
Patients with reflux: When esophageal spasm is associated with significant gastroesophageal reflux (7 of 12 patients in one series), the response to nitroglycerin was unpredictable and less effective 3. In these cases, nitrites may serve only as an adjunct to antireflux therapy 3.
Intravenous administration: A 1995 study demonstrated that intravenous glyceryl trinitrate (100-200 mcg/kg/h) caused dose-dependent elongation of the latency period and significantly decreased contraction duration (from 11.2 to 5.4 seconds), with significant symptom alleviation and notably no adverse effects like headache or blood pressure changes 1.
Important Caveats
Relief with nitroglycerin is not diagnostic of cardiac ischemia, as esophageal spasm demonstrates comparable response to nitrates 4. In one study, 5 of 8 patients with diffuse esophageal spasm had relief with nitroglycerin, but notably, 42 of 49 patients with normal coronary angiograms and normal esophageal manometry also reported relief with nitroglycerin despite having no identifiable esophageal pathology 5.
Practical Administration
Dosing for Esophageal Spasm
Based on FDA labeling for sublingual nitroglycerin and extrapolation from cardiac indications 6:
- Sublingual: 0.3-0.4 mg dissolved under the tongue, may repeat every 5 minutes up to 3 doses 6
- Prophylactic use: 5-10 minutes prior to activities that precipitate symptoms 6
- Long-acting nitrates: For chronic management in responsive patients without reflux, though specific dosing for esophageal spasm is not standardized 3
Contraindications and Precautions
Absolute contraindications 6:
- Recent phosphodiesterase-5 inhibitor use (sildenafil/vardenafil within 24 hours, tadalafil within 48 hours)
- Systolic blood pressure <90 mmHg or ≥30 mmHg below baseline
- Severe bradycardia (<50 bpm) or tachycardia (>100 bpm)
Use with caution 6:
- Volume-depleted patients
- Hypertrophic cardiomyopathy (may aggravate symptoms)
- Patients should sit when taking to prevent falls from orthostatic hypotension
Common Side Effects
- Headache (may indicate drug activity) 6
- Lightheadedness, particularly upon standing 6
- Hypotension 6
- Tolerance may develop with continuous use beyond 24-48 hours 6
Clinical Context and Limitations
Diagnostic Considerations
The British Society of Gastroenterology guidelines note that diffuse esophageal spasm is diagnosed manometrically by at least 20% premature contractions with normal esophagogastric junction relaxation in patients with dysphagia or non-cardiac chest pain 7, 2. However, the clinical relevance of this manometric pattern is debated, as it can be secondary to opioid treatment or observed in asymptomatic patients 2.
Treatment Hierarchy
Medical therapy for esophageal motility disorders is generally disappointing 8. While calcium channel antagonists show good manometric response, clinical symptom improvement is limited 8. The evidence for nitroglycerin, though positive in small series, comes from studies conducted 40-50 years ago without modern trial methodology 3, 5.
Recent endoscopic treatments (botulinum toxin injection, peroral endoscopic myotomy) have been evaluated, though rigorously controlled studies are lacking 2. During POEM procedures for DES, intravenous nitroglycerin has been used intraoperatively to diminish hyperactive spastic contractions 9.
Recent Negative Evidence
A 2020 pilot study of oral nitroglycerin solution for esophageal food impaction (a related but distinct condition) found only 2 of 17 patients (11.8%) achieved symptom resolution, with the rate comparable to placebo 10. This suggests nitroglycerin's efficacy may be limited to specific esophageal spasm scenarios rather than all esophageal smooth muscle dysfunction.
Recommendation
For patients with diffuse esophageal spasm without gastroesophageal reflux, a trial of sublingual nitroglycerin (0.3-0.4 mg as needed) is reasonable based on historical evidence showing consistent benefit in this specific subgroup 3. However, clinicians should recognize that the supporting evidence is limited to small observational studies, and medical therapy overall has poor clinical outcomes for esophageal motility disorders 8. Patients with concurrent reflux should receive antireflux therapy as the primary intervention, with nitrates considered only as adjunctive treatment 3.